Commercially funded grants

Current Grants

Grant Reference	Chief Investigator	Funder	Project Title	Dates and Duration	Total awarded
SGZ-2018-12173	Professor Amit Bahl	Regeneron	EPIC Phase 2 - A Phase II Trial of Cemiplimab alone or in combination with Standard of Care Chemotherapy in Locally Advanced or Metastatic Penile Carcinoma	24/06/2020 - 23/06/2024 (49 months)	£1,109,965
CH/2020/7101	Professor Athimalaipet Ramanan	Novartis Pharmaceuticals UK Ltd.	A Randomised Controlled Trial of Secukinumab Versus Adalimumab for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis, using a Bayesian Design (Turtle)	27/05/2022 - 01/01/2028 (69 months)	£1,552,654
SGZ-2020-13285	Amarnath Challapalli	Regeneron	Efficacy and safety of first line Cemiplimab in advanced basal cell carcinoma (BCC): A phase 2 trial (IMPACT)	01/08/2022 - 31/07/2026 (48 months)	£1,095,139
GSK 219362	Dr Rajeka Lazarus	GSK Pharmaceuticals	A phase IV, multi-centre, randomised controlled trial to assess immunogenicity and safety of COVID-19 and seasonal influenza vaccines given to healthy adults or those with underlying medical conditions when co-administered with a recombinant herpes zoster vaccine with adjuvant (ZosterFluCov)	01/09/2022 - 31/12/2024 (28 months)	£3,778,280

Grant Reference	Chief Investigator	Funder	Project Title	Dates and Duration	Total awarded
1163335	Professor Amit Bahl	Janssen-Cilag Ltd.	The ACE Study: a Phase IV study to evaluate cognitive function in metastatic castrate resistant prostate cancer (mCRPC) patients treated with Abiraterone Acetate (AA) or Enzalutamide (ENZ)	01/04/2018 - 31/03/2022 (48 months)	£851,334